Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-07-01
2008-07-01
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S015800, C514S215000
Reexamination Certificate
active
10661780
ABSTRACT:
A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.
REFERENCES:
patent: 6022860 (2000-02-01), Engel et al.
patent: 6077523 (2000-06-01), Deghenghi
patent: 6319192 (2001-11-01), Engel et al.
patent: WO 9955357 (1999-11-01), None
patent: WO 200059542 (2000-10-01), None
“Will GnRH antagonists provide new hope for patients considered ‘difficult responders’ to GnRH agonist protocols!”, Craft et al., Human Reproduction, vol. 14, No. 12, pp. 2959-2962, 1999.
“Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approch to friendly IVF?”, Engel et al., Human Reproduction, vol. 17, No. 8, pp. 2022-2026, 2002.
“Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles”, Hwang et al., Human Reproduction, vol. 18, No. 1, pp. 45-49, 2003.
“Gonadotropin-releasing hormone anatagonist protocol:a novel method of ovarian stimulation in poor responders”, Nikolettos et al., European Journal of Obstetrics & Gynecology and Reproductive Biology, 97 (2001) 202-207.
Klingmuller et al., “Hormonal responses to the new potent GnRH antagonist Cetrorelix,” Acta Endocrinologica, 128:15-18, Jan. 1993.
Albano et al., “Hormonal Profile During the Follicular Phase in Cycles Stimulated with a Combination of Human Menopausal Gonadotrophin and Gonadotrophin-Releasing Hormone Antagonist (Cetrorelix),”Human Reproduction, vol. 11, No. 10, pp. 2114-2118, 1996.
Awonuga et al., “In vitro Fertilization with Low-Dose Clomiphene Citrate Stimulation in Women Who Respond Poorly to Superovulation,”Journal of Assist Reprod. Genetics, vol. 14, No. 9, pp. 503-507; Oct. 1997.
Diedrich et al., “Suppression of the Endogenous Luteinizing Hormone Surge by the Gonadotrophin-Releasing Hormone Antagonist Cetrorelix During Ovarian Stimulation,”Human Reproduction, vol. 9, No. 5, pp. 788-791, May 1994.
Felberbaum et al.,Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 61, No. 2, pp. 151-515, 1995.
Felberbaum et al., “Hormone Profiles and Pituitary Response Under Ovarian Stimulation With HMG and GnRH Antagonists (Cetrorelix),”Human Reproduction, vol. 9, No. 4, p. 13, 1994.
Jennings et al., “In Vitro fertilisation. A Review of Drug Therapy and Clinical Management,”Drugs, vol. 52, No. 3, pp. 313-343, Sep. 1996.
Leroy et al., “A Single Injection of a Gonadotropin-Releasing Hormone (GnRH) Antagonist (Cetrorelix)* Postpones the Luteinizing Hormone (LH) Surge: Further Evidence for the Role of GnRH During the LH Surge,”Fertility and Sterility, vol. 62, No. 3, pp. 461-467, Sep. 1994.
Olivennes et al., “Scheduled Administration of a Gonadotrophin-Releasing Hormone Antagonist (Cetrorelix) on Day 8 of In-Vitro Fertilization Cycles: A Pilot Study,”Human Reproduction, vol. 10, No. 6, pp. 1382-1386, Jun. 1995.
Olivennes et al., “The Single or Dual Administration of the Gonadotropin-Releasing Hormone Antagonist Cetrorelix* in an In Vitro Fertilization-Embryo Transfer Program,”Fertility and Sterility, vol. 62, No. 3, pp. 468-476, Sep. 1994.
Reissmann et al., “Development and Applications of Luteinizing Hormone-Releasing Hormone Antagonists in the Treatment of Infertility: An Overview,”Human Reproduction, vol. 10, No. 8, pp. 1974-1981, 1995.
Nestor, Jr. et al., “Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity,” J. Med. Chem., Institute of Bio-Organic Chemistry, vol. 35 (No. 21), p. 3942-3948, (Oct. 16, 1992).
Deghenghi et al., “Antarelix (EP 24332) a novel water soluble LHRH antagonist,” Biomed. Pharmacother., Europeptides (Argenteuil, France), vol. 47 (No. 2-3), p. 107-110, (1993).
Rivier et al., “Gonadotropin-releasing hormone antagonists with N omega-triazolylomithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6,” J. Med. Chem., Salk Institute for Biological Studies (La Jolla, California), vol. 35 (No. 23), p. 4270-4278, (Nov. 13, 1992).
Haviv et al., “In vitro and in vivo activities of reduced-size antagonists of luteinizing hormone-releasing hormone,” J. Med. Chem., TAP Pharmaceuticals, Inc. (Abbott Park, IL), vol. 37 (No. 5), p. 701-705, (Mar. 4, 1994).
Weinbauer et al., “Comparison of the antigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis),”Andrologia, Institute of Reproductive Medicine of the University (Munster, Germany), vol. 25, (No. 3), p. 141-147, (May-Jun. 1993).
Bouchard Philippe
Devroey Paul
Diedrich Klaus
Engel Jurgen
Frydman Rene
AEterna Zentaris GmbH
Kwon Brian-Yong S
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
LHRH-antagonists in the treatment of fertility disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with LHRH-antagonists in the treatment of fertility disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LHRH-antagonists in the treatment of fertility disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3915008